+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy



Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy



Leukemia and Lymphoma 56(11): 3096-3102



Ferritin levels might correlate with disease activity in classical Hodgkin lymphoma (cHL). We analyzed the prognostic significance of the ferritin value at diagnosis in 173 cHL patients treated with ABVD between 2003 and 2013. The 5-year overall survival (OS) and progression-free survival (PFS) probabilities were 80% and 64%, respectively. Patients with ferritin ≥ 350 μg/l [high ferritin group (HF), n = 62] were more likely to have advanced stage disease, B-symptoms and higher International Prognostic Score (IPS) compared with patients with ferritin < 350 μg/l [low ferritin group (LF), n = 111]. The complete remission (CR) rate and 5-year PFS and OS probabilities were lower in HF vs. LF patients (69% vs. 89%, p = 0.025; 40% vs. 78%, p < 0.001; 61% vs. 90%, p = 0.001; respectively). Multivariate analysis revealed that advanced stage (p = 0.001) and ferritin levels ≥ 350 μg/l (p = 0.002) were independent predictors for PFS. In conclusion, the ferritin level at diagnosis is a useful prognostic marker for cHL.

(PDF emailed within 0-6 h: $19.90)

Accession: 058835054

Download citation: RISBibTeXText

PMID: 25860241

DOI: 10.3109/10428194.2015.1038709


Related references

Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy. Medical Oncology 31(9): 185, 2015

Rituximala plus ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all international prognostic score (IPS) groups and in patients who have PET positive disease after 2-3 cycles of therapy. 2007

Pulmonary lymphocyte-rich classical Hodgkin lymphoma with early response to ABVD therapy. Annals of Hematology 93(6): 1073-1074, 2014

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood 118(17): 4585-4590, 2012

Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era. Oncotarget 7(44): 72219-72228, 2016

beta(2)-microglobulin in Hodgkin's lymphoma: prognostic significance in patients treated with ABVD or equivalent regimens. Journal of B.U.On. 10(1): 59-69, 2007

Expression of COX-2 on Reed-Sternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD. Blood 119(25): 6072-6079, 2012

Classical Hodgkin lymphoma, lymphocyte depleted type: clinicopathological analysis and prognostic comparison with other types of classical Hodgkin lymphoma. Pathology, Research and Practice 209(4): 201-207, 2013

Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. British Journal of Haematology 170(2): 179-184, 2015

ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. New England Journal of Medicine 366(5): 399-408, 2012

CD68 tumor-associated macrophage marker is not prognostic of clinical outcome in classical Hodgkin lymphoma. Leukemia and Lymphoma 55(5): 1031-1037, 2014

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood 119(18): 4129-4132, 2012

BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 100(12): 3935-3941, 2002

Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood 104(9): 2675-2681, 2004

Prognostic serum cytokines in classical Hodgkin lymphoma--letter. Clinical Cancer Research 20(24): 6633, 2015